Michael Schmidt
Stock Analyst at Guggenheim
(3.68)
# 824
Out of 4,711 analysts
80
Total ratings
51.79%
Success rate
7.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Reiterates: Buy | n/a | $18.48 | - | 2 | Dec 12, 2024 | |
| ADCT ADC Therapeutics | Reiterates: Buy | $10 | $1.96 | +410.20% | 3 | Dec 12, 2024 | |
| BPMC Blueprint Medicines | Reiterates: Buy | n/a | $90.14 | - | 2 | Dec 11, 2024 | |
| TARA Protara Therapeutics | Reiterates: Buy | $20 | $5.39 | +271.06% | 1 | Dec 6, 2024 | |
| MRUS Merus | Maintains: Buy | $93 → $111 | $41.85 | +165.23% | 2 | Dec 5, 2024 | |
| RVMD Revolution Medicines | Maintains: Buy | $82 → $87 | $44.06 | +97.46% | 2 | Dec 3, 2024 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Buy | $12 → $8 | $3.00 | +166.67% | 3 | Nov 15, 2024 | |
| ADAP Adaptimmune Therapeutics | Maintains: Buy | $4 → $3 | $0.60 | +395.95% | 2 | Nov 15, 2024 | |
| EXEL Exelixis | Maintains: Buy | $32 → $33 | $33.29 | -0.87% | 7 | Oct 30, 2024 | |
| IMCR Immunocore Holdings | Downgrades: Neutral | n/a | $28.33 | - | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $4.19 | +210.26% | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $92 | $68.84 | +33.64% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $3.10 | +287.10% | 1 | Aug 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.50 | - | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $10.97 | +219.05% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.00 | - | 2 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 | $1.60 | +337.50% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $345 | $176.50 | +95.47% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.87 | - | 1 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $34 | $24.13 | +40.90% | 4 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $42 | $13.08 | +221.10% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 | $0.91 | +2,097.80% | 3 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 | $8.21 | +82.70% | 3 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $20.31 | - | 2 | Jan 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $2.54 | +884.25% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $6.93 | +332.90% | 1 | Jul 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.64 | - | 2 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $8.50 | - | 4 | Mar 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $80 | $35.42 | +125.86% | 5 | Feb 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.63 | - | 6 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $4 → $5.5 | $3.21 | +71.34% | 2 | Nov 7, 2017 |
Arvinas
Dec 12, 2024
Reiterates: Buy
Price Target: n/a
Current: $18.48
Upside: -
ADC Therapeutics
Dec 12, 2024
Reiterates: Buy
Price Target: $10
Current: $1.96
Upside: +410.20%
Blueprint Medicines
Dec 11, 2024
Reiterates: Buy
Price Target: n/a
Current: $90.14
Upside: -
Protara Therapeutics
Dec 6, 2024
Reiterates: Buy
Price Target: $20
Current: $5.39
Upside: +271.06%
Merus
Dec 5, 2024
Maintains: Buy
Price Target: $93 → $111
Current: $41.85
Upside: +165.23%
Revolution Medicines
Dec 3, 2024
Maintains: Buy
Price Target: $82 → $87
Current: $44.06
Upside: +97.46%
Zentalis Pharmaceuticals
Nov 15, 2024
Maintains: Buy
Price Target: $12 → $8
Current: $3.00
Upside: +166.67%
Adaptimmune Therapeutics
Nov 15, 2024
Maintains: Buy
Price Target: $4 → $3
Current: $0.60
Upside: +395.95%
Exelixis
Oct 30, 2024
Maintains: Buy
Price Target: $32 → $33
Current: $33.29
Upside: -0.87%
Immunocore Holdings
Oct 7, 2024
Downgrades: Neutral
Price Target: n/a
Current: $28.33
Upside: -
Sep 30, 2024
Initiates: Buy
Price Target: $13
Current: $4.19
Upside: +210.26%
Sep 16, 2024
Maintains: Buy
Price Target: $86 → $92
Current: $68.84
Upside: +33.64%
Aug 28, 2024
Initiates: Buy
Price Target: $12
Current: $3.10
Upside: +287.10%
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.50
Upside: -
Apr 15, 2024
Initiates: Buy
Price Target: $35
Current: $10.97
Upside: +219.05%
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.00
Upside: -
Feb 29, 2024
Upgrades: Buy
Price Target: $7
Current: $1.60
Upside: +337.50%
Feb 27, 2024
Maintains: Buy
Price Target: $350 → $345
Current: $176.50
Upside: +95.47%
Jan 5, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.87
Upside: -
Nov 8, 2023
Maintains: Buy
Price Target: $40 → $34
Current: $24.13
Upside: +40.90%
Jul 25, 2023
Maintains: Buy
Price Target: $40 → $42
Current: $13.08
Upside: +221.10%
Jun 27, 2023
Downgrades: Neutral
Price Target: $20
Current: $0.91
Upside: +2,097.80%
Mar 21, 2023
Downgrades: Neutral
Price Target: $15
Current: $8.21
Upside: +82.70%
Jan 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $20.31
Upside: -
Aug 10, 2021
Initiates: Buy
Price Target: $25
Current: $2.54
Upside: +884.25%
Jul 19, 2021
Initiates: Buy
Price Target: $30
Current: $6.93
Upside: +332.90%
Apr 28, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.64
Upside: -
Mar 5, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $8.50
Upside: -
Feb 15, 2019
Upgrades: Outperform
Price Target: $80
Current: $35.42
Upside: +125.86%
Jan 17, 2019
Initiates: Outperform
Price Target: n/a
Current: $5.63
Upside: -
Nov 7, 2017
Maintains: Market Perform
Price Target: $4 → $5.5
Current: $3.21
Upside: +71.34%